Organisation paid for research Program year 2024 Source: CMS Open Payments

Biogenix Molecular LLC

Neither a doctor nor a teaching hospital

Research payments

$479,118

15 payments

Through program year 2024, Biogenix Molecular LLC is reported as receiving $479,118 in research payments, across 15 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2024	Research	$390,536	9
2023	Research	$88,582	6

Breakdown

Who paid Research payments · program years 2023–2024

Blue Earth Diagnostics Limited $390,536 9 payments
Pfizer Inc. $88,582 6 payments

Studies the money was for Research payments · program years 2023–2024

A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto) in Patients With Non-curative Metastatic Prostate Cancer $335,735 7 payments
Global Prevalence of Transthyretin Amyloid Cardiomyopathy Attrcm in Participants With Heart Failure With Preserved Ejection Fraction Hfpef $88,582 6 payments
A Dosimetry Study of Lutetium (177Lu) rhPSMA-10.1 and Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto) in Patients With Non-curative Metastatic Prostate Cancer $54,801 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.